Search global stocks & ETFs...Ctrl K
Learn Mode
MEDP logo

MEDP - Medpace Holdings Inc

233


$420.67

$5.40 (1.300%)
At close: 5/18/26, 8:00 PM
Stock Unlock LogoScore

3.93/5

General
Scores
Financials & KPIs
Dividends
Analyst
Insider
MEDP
Valuation Score
View as %

Stock Unlock Logo
Stock Unlock
$290$627MayJulSepNovJanMar

1D
1W
1M
YTD
1Y
3Y
5Y
Max

Stock Profile
  • Market Cap
    $12.04B
  • Industry
    Life Sciences Tools & Services
  • EPS (TTM)
    $15.89
  • P/E (TTM)
    26.16
  • Div & Yield
    --
  • FCF Payout Ratio
    --
  • P/S (TTM)
    4.50
  • P/B
    20.13
  • Diluted Shares
    28.96M
  • Ex-Dividend
    --
  • Next Earnings
    07-20
  • Forward P/E
    23.77
  • Payout Ratio
    --
  • P/FCF (TTM)
    16.94
  • FCF Yield
    5.90%
  • Earnings Yield
    3.82%
  • 52 Week Range
3.93
Good
Medpace Holdings Inc has grown revenue at 24.19% over the past year, which is strong growth. Also, it has a free cash flow margin of 26.55%, which suggests the company is very profitable.
Valuation Model
Key Score
2.00
Bad
Management
4.00
Good

Growth
5.00
Very Good

Profitability
5.00
Very Good
Fin. Health
1.00
Very Bad

Dividends
--
--

Analyst
4.00
Good
Insider Transactions
Explore Insider Tab
Buy
Sell
20162017201820192020202120222023202420252026$0$250M$500M$750M$1B
Market News
Page 1 of 21
Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-28 16:55:40


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-28 16:51:13


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-28 16:46:36


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-28 16:42:23


Form 10-Q
General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-04-23 16:03:37


Form 8-K
Current report pursuant to Section 13 or 15(d)

Filed on 2026-04-22 16:15:52


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:49:45


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:42:14


Form 4
Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-04-02 16:36:32


Form DEFA14A
Additional definitive proxy soliciting materials

Filed on 2026-04-01 16:42:49


Form DEF 14A
Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-04-01 16:38:54


Form ARS
Unknown Form Type

Filed on 2026-04-01 16:28:28

Page 1 of 21
Revenue
Earnings
Free Cash Flow
2022202320242025$0$650M$1.30B$1.95B$2.60B
Price Targets
Go to Analyst Tab
These are one year price targets for: 2027-04-25
High:
$546.00
29.8%
Avg:
$453.15
7.7%
Low:
$341.82
-18.7%
(% change is relative to the current stock price: $420.67)
Analyst Recommendations
Go to Analyst Tab
3.60
Good
20%
Strong Buy (4)
25%
Buy (5)
50%
Hold (10)
5%
Sell (1)
0%
Strong Sell (0)
About
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company is headquartered in Cincinnati, Ohio and currently employs 6,300 full-time employees. The company went IPO on 2016-08-11. The firm partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The firm also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
  • IPO Date
    2016-08-11
  • Industry
    Life Sciences Tools & Services
  • Total Employees
    6,300
  • Exchange
    Nasdaq Nms - Global Market
  • Reporting Currency
    USD
  • GICS
    Life Sciences Tools & Services
  • GICS Sub
    Life Sciences Tools & Services
  • GICS Sector
    Health Care
  • GICS Group
    Pharmaceuticals, Biotechnology & Life Sciences